

■ Suven Granted Patents for Neurodegenerative Drug



NEW DELHI Pharmaceutical firm Suven Life Sciences on Wednesday said it has been granted one patent each by Australia and Eurasia for drug used in the treatment of neurodegenerative diseases. Neurodegenerative diseases include Alzheimer's disease, Schizophrenia and Parkinson's disease. These patents are valid until 2030 and 2029, respectively, the company said in a BSE filing. Suven Life Sciences CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."

Patent.